EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

The real‐world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody‐associated disease criteria in a Latin American cohort

Edgar Carnero Contentti iD, Claudia Pestchanker, Ethel Ciampi iD, Sheila Castro Suarez, Cesar Caparo Zamalloa iD, Vanesa Daccach Marques, Katharina Messias, José Ignacio Gortari, Verónica Tkachuk, Berenice Silva iD, Carolina Mainella, Saúl Reyes and 5 more

European Journal of Neurology · 2024-12 · 31 (12)

DOI: 10.1111/ene.16445 ↗

At a glance

Journal article in European Journal of Neurology, 2024-12. Written by Edgar Carnero Contentti and 16 co-authors. Institution: Neuroimmunology Unit, Department of Neurosciences, Hospital Aleman, Buenos Aires, Argentina. Major MEDLINE topics: Myelin-Oligodendrocyte Glycoprotein, Autoantibodies. Cited 13 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose The diagnostic criteria for myelin oligodendrocyte glycoprotein antibody (MOG‐IgG)‐associated disease (MOGAD) were published in 2023. We aimed to determine the performance of the new criteria in Latin American (LATAM) patients compared with the 2018 criteria and explore the significance of MOG–IgG titers in diagnosis.

Methods

We retrospectively reviewed the medical records of LATAM (Argentina, Chile, Brazil, Peru, Ecuador, and Colombia) adult patients with one clinical MOGAD event and MOG‐IgG positivity confirmed by cell‐based assay. Both 2018 and 2023 MOGAD criteria were applied, calculating diagnostic performance indicators.

Results

Among 171 patients (predominantly females, mean age at first attack = 34.1 years, mean disease duration = 4.5 years), 98.2% patients met the 2018 criteria, and of those who did not fulfill diagnostic criteria ( n = 3), all tested positive for MOG‐IgG (one low‐positive and two without reported titer). Additionally, 144 (84.2%) patients met the 2023 criteria, of whom 57 (39.5%) had MOG‐IgG+ titer information (19 clearly positive and 38 low‐positive), whereas 87 (60.5%) patients had no MOG‐IgG titer. All 144 patients met diagnostic supporting criteria. The remaining 27 patients did not meet the 2023 MOGAD criteria due to low MOG‐IgG ( n = 12) or lack of titer antibody access ( n = 15), associated with the absence of supporting criteria. The 2023 MOGAD criteria showed a sensitivity of 86% (95% confidence interval = 0.80–0.91) and specificity of 100% compared to the 2018 criteria.

Conclusions

These findings support the diagnostic utility of the 2023 MOGAD criteria in an LATAM cohort in real‐world practice, despite limited access to MOG‐IgG titration.

Subjects

MeSH terms (MEDLINE)

Myelin-Oligodendrocyte GlycoproteinAutoantibodiesHumansFemaleMaleAdultRetrospective StudiesMiddle AgedImmunoglobulin GCohort StudiesChileBrazilPeruColombiaArgentinaEcuadorLatin America

Author keywords

Latin AmericaMOGADdiagnostic criteriaoptic neuritistransverse myelitis

Substances

Myelin-Oligodendrocyte GlycoproteinAutoantibodiesImmunoglobulin GMOG protein, human

Authors and institutions

  • Neuroimmunology Unit, Department of Neurosciences, Hospital Aleman, Buenos Aires, Argentina.
  • Neurology Department, Dr. Ramón Carrillo Central Hospital, San Luis, Argentina.
  • Neurology Department, Hospital Dr. Sótero del Río y Universidad Católica de Chile, Santiago, Chile.
  • Basic Research Center in Dementia and Central Nervous System Demyelinating Diseases, Instituto Nacional de Ciencias Neurológicas, Lima, Peru.
  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.
  • Neurology private practice, Pereira, Colombia.

ORCID profiles: Edgar Carnero Contentti, Ethel Ciampi, Cesar Caparo Zamalloa, Berenice Silva

Cite

APA

Carnero Contentti, E., Pestchanker, C., Ciampi, E., Castro Suarez, S., Caparo Zamalloa, C., Daccach Marques, V., Messias, K., Gortari, J. I., Tkachuk, V., Silva, B., Mainella, C., Reyes, S., Toro, J., Rodriguez, J., Correa-Diaz, E., Rojas, J. I., & Paul, F. (2024). The real‐world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody‐associated disease criteria in a Latin American cohort. European Journal of Neurology. https://doi.org/10.1111/ene.16445

Vancouver

Carnero Contentti E, Pestchanker C, Ciampi E, Castro Suarez S, Caparo Zamalloa C, Daccach Marques V, et al. The real‐world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody‐associated disease criteria in a Latin American cohort. European Journal of Neurology. 2024. doi:10.1111/ene.16445

BibTeX
@article{CarneroContentti2024,
  author = {Carnero Contentti, Edgar and Pestchanker, Claudia and Ciampi, Ethel and Castro Suarez, Sheila and Caparo Zamalloa, Cesar and Daccach Marques, Vanesa and Messias, Katharina and Gortari, José Ignacio and Tkachuk, Verónica and Silva, Berenice and Mainella, Carolina and Reyes, Saúl and Toro, Jaime and Rodriguez, Juan and Correa-Diaz, Edgar and Rojas, Juan I and Paul, Friedemann},
  title = {The real‐world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody‐associated disease criteria in a Latin American cohort},
  journal = {European Journal of Neurology},
  year = {2024},
  doi = {10.1111/ene.16445}
}
Start for free →